BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The biggest black hole breakthroughs of 2025 - 2Immortal Style: Closet Staples for Each Age
- 3Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- 4Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 5RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- Monetary Security: Building Serious areas of strength for an Establishment
- Antimatter took to the road for the very first time. Here’s why it matters
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- Artemis II crew take new photo of far side of the moon
- Figure out How to Score Huge with Open Record Rewards
- Israeli strike on Gaza City vehicle kills at least four, report says
- The Incomparable Advanced cameras: Which One Will Win?
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- Far-right German youth group delegates seek deportations, remigration
